Chicken Pox (Varicella) Vaccines
The chickenpox vaccine is a shot that can protect nearly anyone who receives the vaccine from catching chickenpox. It's also called the varicella vaccine, because chickenpox is caused by the varicella-zoster virus. The vaccine is made from a live but weakened, or attenuated, virus. Viruses that have been attenuated are less virulent than viruses that are not. Although the virus in the chickenpox vaccine is generally incapable of causing a disease, it still stimulates a response from the body's immune system. That response is what gives someone who's had a shot for chickenpox immunity or protection from the illness.
- Chickenpox immunity
- Hospitalizations
- Complications
- chickenpox blisters
- Lesion by chicken pox
Related Conference of Chicken Pox (Varicella) Vaccines
March 24-25, 2026
9th International Conference on Vaccines, Immunology and Clinical Trials
Paris, France
Chicken Pox (Varicella) Vaccines Conference Speakers
Recommended Sessions
- Bacterial Vaccines
- Chicken Pox (Varicella) Vaccines
- Current Research and Future Challenges
- Entrepreneurs Investment Meet
- Flu Vaccines
- Haemophilus Influenza Type b (Hib) Vaccines
- Hepatitis Vaccines
- Human Papillomavirus (HPV) Vaccines
- Immunization safety
- Maternal Immunity
- Meningococcal Vaccines
- Multiple Vaccines (or) Combination Vaccines
- Neonatal Vaccines
- Polio Vaccines
- PPSV (Pneumococcal Vaccines)
- Rotavirus (RV) Vaccines
- Smallpox Vaccines
- Standard Immunizations For Children
- Vaccine Adjuvants
- Vaccine Delivery Technologies
- Vaccine Production and Development
- Vaccine Storage and Handling
- Vaccines For Pregnant Women
Related Journals
Are you interested in
- Adjuvants and Immunopotentiators - VACCINE CONGRESS 2025 (Japan)
- Adult and Elderly Vaccination Strategies - VACCINE CONGRESS 2025 (Japan)
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Adverse reactions to the vaccination - Vaccines Congress-2025 (Canada)
- AI and Data Science in Vaccine Discovery - VACCINE CONGRESS 2025 (Japan)
- Antimicrobial Resistance and Vaccines - VACCINE CONGRESS 2025 (Japan)
- Antinatal vaccinations - Vaccines Congress-2025 (Canada)
- Booster Doses and Heterologous Vaccine Regimens - VACCINE CONGRESS 2025 (Japan)
- Cancer Vaccines and Immunotherapy - VACCINE CONGRESS 2025 (Japan)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Conjugated and combination vaccinations - Vaccines Congress-2025 (Canada)
- Corporate Innovation, Sponsorship & Exhibition - VACCINE CONGRESS 2025 (Japan)
- COVID-19 Vaccine Impact and Learnings - VACCINE CONGRESS 2025 (Japan)
- Creation and development of vaccines - Vaccines Congress-2025 (Canada)
- DNA, RNA & SYNTHETIC VACCINES - Vaccines Congress-2025 (Canada)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Global Immunization Programs and Policy - VACCINE CONGRESS 2025 (Japan)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- HIV , Malaria & TB vaccines - Vaccines Congress-2025 (Canada)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Infectious Disease Vaccines - VACCINE CONGRESS 2025 (Japan)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Manufacturing, Supply Chain, and Distribution - VACCINE CONGRESS 2025 (Japan)
- Nanotechnology in Vaccine Delivery - VACCINE CONGRESS 2025 (Japan)
- Next-Generation Vaccine Technologies - VACCINE CONGRESS 2025 (Japan)
- Pediatric and Neonatal Vaccines - VACCINE CONGRESS 2025 (Japan)
- rDNA technology in vaccine development - Vaccines Congress-2025 (Canada)
- Recent advances in vaccine development - Vaccines Congress-2025 (Canada)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- The COVID-19 vaccine's next-generation RNA platforms and mRNA - Vaccines Congress-2025 (Canada)
- Toxoid vaccination - Vaccines Congress-2025 (Canada)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Vaccine and Vaccination - Vaccines Congress-2025 (Canada)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine efficiency and well-being - Vaccines Congress-2025 (Canada)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine for infectious illnesses in humans - Vaccines Congress-2025 (Canada)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine manufacturing technologies - Vaccines Congress-2025 (Canada)
- Vaccine Research and Clinical trials - Vaccines Congress-2025 (Canada)
- Vaccine Research Ethics and Regulations - VACCINE CONGRESS 2025 (Japan)
- Vaccine Safety and Pharmacovigilance - VACCINE CONGRESS 2025 (Japan)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccines against non-traditional illnesses - Vaccines Congress-2025 (Canada)
- VACCINES FOR CANCER - Vaccines Congress-2025 (Canada)
- Veterinary and Zoonotic Vaccines - VACCINE CONGRESS 2025 (Japan)
- Workshops and Poster Sessions - VACCINE CONGRESS 2025 (Japan)
- Zika Virus vaccines - Vaccines Congress-2025 (Canada)